Background: Abnormal amyloid-β protein precursor (AβPP) metabolism is a key feature of Alzheimer’s disease (AD). Platelets contain most of the enzymatic machinery required for AβPP processing, and correlates of intracerebral abnormalities have been demonstrated in platelets of patients with AD. Thus, AβPP-related molecules in platelets may be regarded as peripheral markers of AD.
Objective: We sought to determine the protein expression of the AβPP secretases (ADAM10, BACE1, and PSEN1) and AβPP ratio in platelets of patients with mild or moderate AD compared to healthy controls. We further determined whether the protein expression of these markers might be modified by chronic treatment with donepezil.
Methods: Platelet samples were obtained from patients and controls at baseline and after 3 and 6 months of continuous treatment with therapeutic doses of donepezil. The protein expression of platelet markers was determined by western blotting.
Results: AD patients had a significant decrease in AβPP ratio, ADAM10, and PSEN1 compared to controls at baseline, but these differences were not modified by the treatment. Nonetheless, a significant reduction in the protein expression of BACE1 was observed in patients treated with donepezil for 6 months.
Conclusion: Our results corroborate previous findings from our group and others of decreased AβPP ratio and protein expression of ADAM10 in AD. We further show that PSEN1 is decreased in AD platelets, and that the protein expression of BACE1 is downregulated by chronic treatment with donepezil. This effect may be interpreted as evidence of disease modification.
GoldgaberD, LermanMI, McBrideOW, SaffiottiU, GajdusekDC (1987) Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer’s disease. Science235, 877–880.
2.
ChangC, WerbZ (2001) The many faces of metalloproteases: Cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol11, S37–S43.
3.
SealsDF, CourtneidgeSA (2003) The ADAMs family of metalloproteases: Multidomain proteins with multiple functions. Genes Dev17, 7–30.
4.
SoderoACR, De SimoneSG, Silva-JrFP (2009) Mecanismo catalítico e estado de protonação do sítio ativo de aspartil proteases pepsina-símiles. Rev Virtual Quim1, 128–137.
5.
SchellenbergGD, BirdTD, WijsmanEM, OrrHT, AndersonL, NemensE, WhiteJA, BonnycastleL, WeberJL, AlonsoME, PotterH, HestonLL, MartinGM (1992) Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14. Science258, 668–671.
6.
BushAI, MartinsRN, RumbleB, MoirR, FullerS, MilwardE, CurrieJ, AmesD, WeidemannA, FischerP, MulthaupG, BeyreutherK, MastersCL (1990) The amyloid precursor protein of Alzheimer’s disease is released by human platelets. J Biol Chem265, 15977–15983.
7.
GardellaJE, GhisoJ, GorgoneGA, MarrattaD, KaplanAP, FrangioneB, GorevicPD (1990) Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA. Biochem Biophys Res Commun173, 1292–1298.
8.
PadovaniA, BorroniB, ColciaghiF, PastorinoL, ArchettiS, CottiniE, CaimiL, CattabeniF, Di LucaM (2001) Platelet amyloid precursor protein forms in AD: A peripheral diagnostic tool and a pharmacological target. Mech Ageing Dev122, 1997–2004.
9.
TangK, HynanLS, BaskinF, RosenbergRN (2006) Platelet amyloid precursor protein processing: A bio-marker for Alzheimer’s disease. J Neurol Sci240, 53–58.
10.
RosenbergRN, BaskinF, FosmireJA, RisserR, AdamsP, SvetlikD, HonigLS, CullumCM, WeinerMF (1997) Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol54, 139–144.
11.
Di LucaM, PastorinoL, BianchettiA, PerezJ, ViagnoloLA, LenziGL, TrabucchiM, CattebeniF, PadovaniA (1998) Differential level of platelet amyloid β precursor protein isoforms – an early marker for Alzheimer disease. Arch Neurol55, 1195–1200.
12.
Di LucaM, ColciaghiF, PastorinoL, BorroniB, PadovaniA, CattabeniF (2000) Platelets as a peripheral district were to study pathogenetic mechanisms of Alzheimer disease: The case of amyloid precursor protein. Eur J Pharmacol405, 277–283.
13.
ZainaghiIA, TalibLL, DinizBS, GattazWF, ForlenzaOV (2012) Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer’s disease. J Neural Transm119, 815–819.
14.
ZainaghiIA, ForlenzaOV, GattazWF (2007) Abnormal APP processing in platelets of patients with Alzheimer’s disease: Correlations with membrane fluidity and cognitive decline. Psychopharmacology (Berl)192, 547–553.
15.
ColciaghiF, MarcelloE, BorroniB, ZimmermannM, CaltagironeC, CattabeniF, PadovaniA, DiLuca M (2004) Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology62, 498–501.
16.
PakaskiM, KasaP (2003) Role of acetylcholinesterase inhibitors in the metabolism of amyloid precursor protein. Curr Drug Target CNS Neurl Disord3, 163–171.
17.
ZimmermannM, GardoniF, MarcelloE, ColciaghiF, BorroniB, PadovaniA, CattabeniF, DiLuca M (2004) Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J Neurochem90, 1489–1499.
18.
LiQ, ChenM, LiuH, YangL, YangG (2012) Expression of APP, BACE1, AChE and ChAT in an AD model in rats and the effect of donepezil hydrochloride treatment. Mol Med Rep6, 1450–1454.
19.
SilveyraMX, García-AyllónMS, Serra-BasanteC, MazzoniV, García-GutierrezMS, ManzanaresJ, CulvenorJG, Sáez-ValeroJ (2012) Changes in acetylcholinesterase expression are associated with altered presenilin-1 levels. Neurobiol Aging33, 627–637.
20.
Di LucaM, GrossiE, BorroniB, ZimmermannM, MarcelloE, ColciaghiF, GardoniF, IntraligiM, PadovaniA, BuscemaM (2005) Artificial neural networks allow the use of simultaneous measurements of Alzheimer disease markers for early detection of disease. J Transl Med3, 30.
21.
ZimmermannM, BorroniB, CattabeniF, PadovaniA, Di LucaM (2005) Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol Dis19, 237–242.
AmericanPsychiatric Association (2000) Diagnostic and statistical manual of mental disorders (4th ed., text rev.) Arlington, VA.
25.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
26.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
27.
RothM, TymE., MountjoyCO, HuppertFA, HendrieH, VermaS, GoddardR (1986) CAMDEX: A standardized instrument for the diagnosis of mental disorders in the elderly with special reference to the early detection of dementia. Br J Psychiatry149, 698–709.
28.
LowryOH, RosebroughNJ, FarrAL, RandallRJ (1951) Protein measurement with the folin-phenol reagents. J Biol Chem193, 265–275.
29.
ManzinePR, de França BramJM, BarhamEJ, do Vale FdeA, Selistre-de-AraújoHS, CominettiMR, Iost PavariniSC (2013) ADAM10 as a biomarker for Alzheimer’s disease: A study with Brazilian elderly. Dement Geriatr Cogn Disord35, 58–66.
30.
DecourtB, WalkerA, GonzalesA, Malek-AhmadiM, LiesbackC, DavisKJ, BeldenCM, JacobsonSA, SabbaghMN (2013) Can platelet BACE1 levels be used as a biomarker for Alzheimer’s disease? Proof-of-concept study. Platelets24, 235–238.
31.
BorroniB, ColciaghiF, PastorinoL, ArchettiS, CorsiniP, CattabeniF, Di LucaM, PadovaniA (2002) ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: Evidence from a peripheral model. Eur Neuropsychopharmacol12, 195–200.
32.
LuoY, BolonB, KahnS, BennettBD, Babu-KhanS, DenisP, FanW, KhaH, ZhangJ, GongY, MartinL, LouisJC, YanQ, RichardsWG, CitronM, VassarR (2001) Mice deficient in BACE1, the Alzheimer’s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci4, 231–232.
33.
GhoshAK, TangJ (2015) Prospects of β-secretase inhibitors for the treatment of Alzheimer’s disease. Chem Med Chem10, 1463–1466.
34.
OhnoM, SametskyEA, YounkinLH, OakleyH, YounkinSG, CitronM, VassarR, DisterhoftJF (2004) BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer’s disease. Neuron41, 27–33.
35.
OhnoM, ColeSL, YasvoinaM, ZhaoJ, CitronM, BerryR, DisterhoftJF, VassarR (2007) BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol Dis26, 134–145.
36.
DavisJ, CouchR (2014) Strategizing the development of Alzheimer’s therapeutics. Adv Alzheimer Dis3, 107–127.
37.
MentingKW, ClaassenJAHR (2014) β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease. Front Aging Neurosci6, 165.
38.
StellaF, RadanovicM, CanineuPR, de PaulaVJ, ForlenzaOV (2015) Anti-dementia medications: Current prescriptions in clinical practice and new agents in progress. Ther Adv Drug Saf6, 151–165.
